5 Stocks to Buy on a Pullback

Page 5 of 5

1. AbbVie Inc. (NYSE:ABBV)

On April 20, 2026, Canaccord initiated coverage of AbbVie Inc. (NYSE:ABBV) with a Buy rating and a $262 price target on the shares, offering an upside potential of around 29% from AbbVie Inc. (NYSE:ABBV)’s last close.

On April 12, 2026, CollPlant disclosed that Allergan Industrie SAS, an AbbVie company, exercised its right to terminate a development agreement originally signed in February 2021, with termination taking effect after a 60-day notice period. The partnership had focused on developing dermal and soft tissue fillers using CollPlant’s rhCollagen technology for the medical aesthetics market. Despite the termination, CollPlant indicated it continues to see strong interest in its collagen platform and is actively pursuing new partnerships, including discussions with multiple strategic and Tier 1 companies for potential collaborations in aesthetic applications.

A day earlier, AbbVie Inc. (NYSE:ABBV) announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented at the 2026 Society of Gynecologic Oncology Annual Meeting. The study evaluated mirvetuximab soravtansine-gynx (Elahere) in combination with carboplatin, followed by monotherapy maintenance, in patients with folate receptor alpha-positive, platinum-sensitive ovarian cancer. The trial enrolled 125 patients and focused on objective response rate as the primary endpoint, with additional measures including duration of response, progression-free survival, and overall survival.

AbbVie Inc. (NYSE:ABBV) develops and markets pharmaceutical therapies across multiple therapeutic areas globally.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Stocks That Beat Earnings Estimates and  10 Best 52-Week Low NASDAQ Stocks to Buy Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 5 of 5